Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors

Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.

(2019) Matthew Reilley et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors

(2018) Elizabeth A. Kuczynski et al.   MOLECULAR CANCER THERAPEUTICS

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

(2018) Carsten Krieg et al.   NATURE MEDICINE

Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution

(2018) Mirjana Efremova et al.   Nature Communications

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study

(2018) M Thomas et al.   ANNALS OF ONCOLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

(2018) Antoni Ribas et al.   Cancer Discovery

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

(2018) A Marabelle et al.   ANNALS OF ONCOLOGY

Targeting macrophages: therapeutic approaches in cancer

(2018) Luca Cassetta et al.   NATURE REVIEWS DRUG DISCOVERY

Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments

(2018) Jong W. Yu et al.   PLoS One

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon

(2017) A R Krarup et al.   Mucosal Immunology

Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy

(2017) Xiang Zheng et al.   Oncotarget

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

(2016) Peter Ellmark et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Basis of Oncoimmunology

(2016) A. Karolina Palucka et al.   CELL

Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment

(2016) Stefani Spranger   INTERNATIONAL IMMUNOLOGY

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells

(2016) Shu Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

(2015) Burghardt Wittig et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours

(2015) Martin R. Weihrauch et al.   EUROPEAN JOURNAL OF CANCER

The interaction of anticancer therapies with tumor-associated macrophages

(2015) Alberto Mantovani et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703

(2015) Manuel Schmidt et al.   Nucleic Acid Therapeutics

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

(2014) John C Castle et al.   BMC GENOMICS

Intratumoral Immunization: A New Paradigm for Cancer Therapy

(2014) A. Marabelle et al.   CLINICAL CANCER RESEARCH

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

(2014) Hans-Joachim Schmoll et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Genuine Immunomodulation With dSLIM

(2014) Kerstin Kapp et al.   Molecular Therapy-Nucleic Acids

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

(2013) Melissa G. Lechner et al.   JOURNAL OF IMMUNOTHERAPY

Tumor-associated macrophages: functional diversity, clinical significance, and open questions

(2013) Subhra K. Biswas et al.   Seminars in Immunopathology

New developments in Toll-like receptor targeted therapeutics

(2012) Dympna J Connolly et al.   CURRENT OPINION IN PHARMACOLOGY

Trial Watch

(2012) Lorenzo Galluzzi et al.   OncoImmunology

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

(2011) Mark S. Diamond et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

(2010) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY

Signalling pathways leading to IFN-α production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications

(2008) C. Guiducci et al.   JOURNAL OF INTERNAL MEDICINE